Related Experiment Videos
[Proglumetacine in rheumatoid arthritis]
Minerva Medica
|June 23, 1983
Summary
Proglumetacin effectively treated rheumatoid arthritis in over 50% of patients, significantly reducing pain and inflammation, especially in early-stage disease. This non-steroidal anti-inflammatory drug demonstrated good tolerance compared to other agents.
Area of Science:
- Rheumatology
- Pharmacology
Context:
- Rheumatoid arthritis (RA) is a chronic autoimmune disease causing joint inflammation and pain.
- Current treatments include non-steroidal anti-inflammatory drugs (NSAIDs), but efficacy and tolerance vary.
- Evaluating novel NSAIDs like proglumetacin is crucial for RA management.
Purpose:
- To assess the efficacy and safety of proglumetacin in patients with rheumatoid arthritis.
- To compare proglumetacin's effectiveness against other NSAIDs.
Summary:
- Proglumetacin (450 mg/day) was given to 32 rheumatoid arthritis patients (Stage II-III) for one month.
- Over 50% of patients responded, with significant improvements in Ritchie's articular index and pain scores in Stage II patients.
- Patients unresponsive to proglumetacin also did not respond to indomethacin. Adverse events were mild and transient, with no central nervous system effects.
Impact:
- Proglumetacin shows high efficacy and good tolerance in rheumatoid arthritis patients.
- It offers a promising alternative to indomethacin, aspirin (A.S.A.), and other NSAIDs.
- Further research may establish proglumetacin as a valuable therapeutic option for RA.